Rapid Micro Biosystems (RPID) Preferred Stock Liabilities (2020 - 2021)
Rapid Micro Biosystems recorded quarterly Preferred Stock Liabilities of $235.8 million in Q2 2021, up 0.86% quarter-over-quarter from $233.8 million in Q1 2021, and up 60.1% year-over-year from $147.3 million in Q2 2020.
Rapid Micro Biosystems' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $235.8 million for Q2 2021.
- In Q2 2021, Preferred Stock Liabilities rose 60.1% year-over-year to $235.8 million; the TTM figure through Jun 2021 stood at $235.8 million (up 60.1% YoY), while the FY2020 annual figure was $4.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $235.8 million for Q2 2021 at Rapid Micro Biosystems, up from $233.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $235.8 million in Q2 2021 to a low of $4.1 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Rapid Micro Biosystems | 89.50 Mn | 66.56 Mn | 371,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 235.84 Mn |
| Mar 31, 2021 | 233.83 Mn |
| Dec 31, 2020 | 4.12 Mn |
| Sep 30, 2020 | 149.55 Mn |
| Jun 30, 2020 | 147.31 Mn |